Helius Opens New Site for Pivotal Mild to Moderate Traumatic Brain Injury Trial at HealthTech Connex in Surrey, British Columbia

NEWTOWN, PENNSYLVANIA and SURREY, BRITISH COLUMBIA–(Marketwired – Aug. 31, 2016) – Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) (“Helius” or the “Company”) is pleased to announce HealthTech Connex Inc. (“HTC”) in Surrey, British Columbia, will be the fourth site for the company’s ongoing pivotal trial investigating PoNS™ Therapy for the treatment of subjects with balance disorder resulting from mild to moderate Traumatic Brain Injury (TBI). Clinical trial sites in the U.S. and Canada include the Montreal Neurofeedback Center, Oregon Health and Science University and Orlando Regional Medical Center.
“We are thrilled to be expanding our clinical presence and look forward to working with the dedicated team of professionals HTC has assembled to facilitate this study,” said Helius CEO, Phil Deschamps. “The shared vision to improve care for those suffering from brain injuries connected Helius with HealthTech Connex. Their expertise in neurotechnology, brain imaging and brain trauma, as well as their broad network in the TBI community provides a sound foundation for adding this fourth PoNS™ clinical trial site.”
“HealthTech Connex is excited to be a service provider for Helius, with our new facilities at the Health & Technology District in Surrey,” said Dr. Ryan D’Arcy, HTC President & Chief Scientific Officer. “Furthering the understanding of neuroplasticity and pioneering treatments for brain injury are our common goals as we investigate potential solutions to this considerable unmet medical need.”
To learn more about the clinical trial, the clinical trial sites and recruitment opportunities please visit www.heliusmedical.com/our-research/clinical-trials.
About PoNS™ Therapy
The Portable Neuromodulation Stimulator (PoNS™) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS™ Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. Helius intends to file for FDA clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.
About HealthTech Connex Inc.
HealthTech Connex, Inc. is a health technology company working to revolutionize the practice of clinical neuroscience through advanced technologies based on the highest quality science and innovation. Located in Surrey, British Columbia, Canada, it is one of the first companies to emerge from the city’s Innovation Boulevard, an agile partnership of health, business, higher education and government creating new health technologies to improve peoples’ lives. www.HTCBrainVitalSigns.com
The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Cautionary Disclaimer Statement:
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).
All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory approvals, business initiatives and objectives and use of proceeds from financings or other business initiatives.
Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure of the Company to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s disclosure materials, including the short form prospectus filed in connection with the Offering, its Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.
The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.